Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Relmada Therapeutics ( (RLMD) ) has issued an update.
On November 4, 2025, Relmada Therapeutics announced FDA feedback on its proposed NDV-01 Phase III trials and shared nine-month safety and efficacy data for its Phase II study in high-risk NMIBC patients. The FDA’s feedback suggests a single-arm trial may be acceptable for BCG-unresponsive patients, and a randomized study for intermediate-risk NMIBC patients is generally acceptable, pending further discussions. The nine-month data showed no new safety signals and a high complete response rate among patients. The company also reported preliminary financial information, indicating approximately $13.9 million in cash and investments as of September 30, 2025.
The most recent analyst rating on (RLMD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for central nervous system disorders. The company is committed to advancing its pipeline of innovative treatments, including its lead product candidate, NDV-01, which targets non-muscle invasive bladder cancer (NMIBC).
Average Trading Volume: 735,892
Technical Sentiment Signal: Hold
Current Market Cap: $73.02M
Find detailed analytics on RLMD stock on TipRanks’ Stock Analysis page.